Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

Prostate cancer (PCa) is one of the most common cancers in men that usually develops slowly. Since diagnostic methods improved in the last decade and are highly precise, more cancers are diagnosed at an early stage. Active surveillance or watchful waiting are appealing approaches for men diagnosed with low-risk prostate cancer, and they are an antidote to the overtreatment problem and unnecessary biopsies. However, treatment depends on individual circumstances of a patient. Older hormonal therapies based on first generation antiandrogens and steroids were widely used in metastatic castration-resistant prostate cancer (mCRPC) patients prior to the implementation of docetaxel. Nowadays, accordingly to randomized clinical trials, abiraterone, enzalutamide, apalutamide. and docetaxel became first line agents administrated in the treatment of mCRPC. Furthermore, radium-223 is an optional therapy for bone-only metastasis patients. Sipuleucel-T demonstrated an overall survival benefit. However, other novel immunotherapeutics showed limitations in monotherapy. Possible combinations of new vaccines or immune checkpoint blockers with enzalutamide, abiraterone, radium-223, or docetaxel are the subject of ongoing rivalry regarding optimal therapy of prostate cancer.

Enzalutamide

Abiraterone acetate

Abiraterone

Hormonal Therapy

10.3390/diagnostics9040161

Cite

Citations (24)

New treatment options for patients with metastatic prostate cancer.

The Netherlands Journal of Medicine (2013)

Lobke Snoeks Aernout C. Ogilvie Ernst P. van Haarst C. E. H. Siegert

Cabazitaxel

Enzalutamide

Radium-223

Abiraterone

Abiraterone acetate

Source

Cite

Citations (11)

Number Needed to Treat and Cost Per Clinically Meaningful Outcome of Enzalutamide and Abiraterone Acetate for The Treatment of Metastatic Castration-Resistant Prostate Cancer That Failed Androgen Deprivation Therapy in Brazil

Value in Health (2016)

AP Sasse Gilberto Lopes V Teich AP Fay Mahzad Roostaei Hosein Abadi

Enzalutamide

Abiraterone acetate

Abiraterone

10.1016/j.jval.2016.09.2151

Cite

Citations (0)

Serial genotypic characterization of circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) undergoing treatment with abiraterone acetate (abi) or enzalutamide (enza)

Annals of Oncology (2017)

Nazlı Dizman Jaymala Patel Miaoling He Brad Foulk Denis A. Smirnov

Enzalutamide

Circulating tumor cell

10.1093/annonc/mdx390.042

Cite

Citations (0)

Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer.

Lorie Ellis Marie‐Hélène Lafeuille Laurence Gozalo Dominic Pilon Patrick Lefèbvre

Background The approval of new therapies for metastatic castration-resistant prostate cancer (mCRPC), including the oral agents abiraterone acetate and enzalutamide, has altered the standard of care for patients with mCRPC. Little information exists regarding the sequences in which new therapies for mCRPC with evidence of survival benefits are used.

Enzalutamide

Abiraterone acetate

Abiraterone

Cite

Citations (19)

Supplementary Fig. 3 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

Emmanuel S. Antonarakis Sumit K. Subudhi Christopher Pieczonka Lawrence I. Karsh David I. Quinn

Supplementary Fig 3 In vivo cellular and humoral responses through 52 weeks are illustrated here.

Enzalutamide

Abiraterone acetate

STRIDE

Bicalutamide